Image courtesy of Pexels.

Imagine waking up with the flu one morning, calling out sick, and spending time resting and recovering. A week passes, and symptoms linger. Then two or three weeks slip by, and still no relief. Now picture over 100 weeks passing with the same unrelenting illness.

One man experienced this with COVID-19, worsened by his suppressed immune system. He endured acute symptoms for more than 750 days. Throughout this time, he visited the hospital five times because of his constant respiratory struggles.

What Do We Know About the Man’s Long-Lasting COVID-19 Acute Phase?

Though his illness stretched over two years, doctors did not classify it as Long COVID. In Long COVID, symptoms remain even after viral activity has stopped. In this case, the acute phase of SARS-CoV-2 infection stayed active for more than 750 days.

Researchers conducted genome analysis on viral samples collected between March 2021 and July 2022. They found the virus mutated at a rate consistent with typical SARS-CoV-2 progression. Some mutations mirrored those of known variants, including Omicron.

The study suggested the man’s infection was moving in the same direction as the evolutionary path that led to Omicron. This finding supports the theory that Omicron emerged, at least in part, from selection processes within chronically infected hosts.

The man, age 40, was also diagnosed with advanced HIV-1. He likely contracted COVID-19 in mid-May 2020, during a period when he was not receiving antiretroviral therapy. He reported difficulty accessing medical care despite severe symptoms.

His helper T-cell count measured only 35 cells per microliter of blood, far below the normal range of 500 to 1,500. This severely weakened immune system helps explain why the infection persisted for so long.

Fortunately, his particular strain did not appear highly transmissible. Researchers noted no evidence that his case posed unusual risk to those around him.

What Does This Case Mean for Understanding COVID-19?

At first glance, the man’s prolonged illness might seem like an edge case affecting only the most vulnerable. But researchers stress that such infections have wider implications. When a virus incubates for months or even years, it undergoes selective mutations inside the host. These changes can help the virus adapt, making it more efficient at entering cells and replicating.

Chronic infections like this create opportunities for more infectious variants to emerge. That’s why medical professionals see these cases as both an individual health concern and a communal risk. While this man’s particular infection did not lead to a highly transmissible strain, other prolonged cases might. Evolutionary processes are unpredictable, and the development of new variants remains a possibility.

For this reason, experts urge caution and continued vigilance. They emphasize the need for monitoring long-term infections, expanding healthcare access, and keeping communities protected through up-to-date vaccinations. They also recommend masking in crowded or enclosed areas to reduce the chance of spread.

How Did Researchers Study This Case?

The man was first diagnosed with HIV in 2002, but was not on antiretroviral therapy at the time of his COVID-19 infection. His severely weakened immune system left him unable to clear the virus. After his death, researchers received approval to analyze samples without requiring consent.

They collected eight swab samples from him between March 2021 and July 2022. These were taken at intervals ranging from 312 to 776 days after symptom onset. Genome sequencing of the samples revealed mutations that tracked alongside known patterns of COVID-19 evolution, including similarities to Omicron.

What Were the Study’s Limitations?

Researchers acknowledged several limits to their findings. Only a few samples were collected, and the exact timing of the man’s initial infection could not be confirmed. It was also difficult to obtain consistent samples because he had limited access to medical care.

Importantly, his case was extreme. Antiretroviral therapy often helps people with HIV recover more effectively from COVID-19. The patient was also unvaccinated, a factor that may have worsened the severity of his illness. He ultimately died from unrelated causes, not from the infection itself.

Still, the study underscores how SARS-CoV-2 can create prolonged, non-lethal infections in immunosuppressed individuals. Because these infections provide opportunities for viral mutation, experts stress that eliminating them should be a global health priority.

Conclusion

This man’s prolonged illness highlights how weakened immunity can allow SARS-CoV-2 to persist and mutate. While his infection did not generate a dangerous new variant, similar cases could. Researchers stress the importance of monitoring chronic infections, improving healthcare access, and maintaining strong public health measures.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pexels.

Unlike in Mary Shelley’s Frankenstein, electricity cannot reanimate dead bodies. Yet new research shows the fictional idea isn’t far off. Electrical stimulation may boost the body’s natural healing processes.

Researchers at Trinity College Dublin found that electrical stimulation can reboot macrophages. These white blood cells either move through tissues or reside within them. At injury sites, they reduce inflammation and accelerate healing. The findings could lead to breakthroughs in treating injuries and disease.

What Are Macrophages?

Macrophages are powerful defenders that boost the body’s immune system. As these white blood cells circulate, they clear disease, debris, and damaged cells. They also recruit other immune cells during infections or injuries.

But macrophages are not always helpful. When overactive, they can fuel excessive inflammation and worsen damage. Because of this, managing macrophage activity is a critical treatment factor in disease.

How Can Electrical Stimulation Boost Healing?

Researchers tested this idea in the lab. They isolated macrophages from donated human blood and placed them in a custom bioreactor. Electrical currents were applied to the cells while their responses were monitored.

Results showed electrical stimulation boosted the macrophages’ anti-inflammatory activity. In treatment, this could reduce tissue damage and speed healing. The team saw reduced inflammation and greater gene expression for blood vessel growth. Both processes are essential to tissue repair.

Electrical stimulation also increased stem cell activity at wound sites. This response further enhanced tissue repair and healing outcomes.

What Future Research Should These Results Promote?

Future research could clarify how electrical stimulation triggers these macrophage effects. The findings may also guide the design of new drug treatments that target macrophage activity.

Other studies could explore demographic factors like age and sex. These variables strongly influence the immune system, but donor regulations prevented such analysis in this study.

It will also be important to test these results in living organisms. Supplementing lab experiments with in vivo models would strengthen the evidence.

What Possible New Therapies Could Emerge?

The study’s authors say their work confirms long-standing evidence. Macrophages play a central role in fighting infection and repairing tissue.

Scientists aim to make macrophages quicker and more effective. Researchers also continue efforts to limit the harmful inflammation caused by overactive macrophages.

Because these experiments used human blood cells, real-world applications may be close. Electrical stimulation is also considered a low-risk treatment method. With potential benefits for both wounds and disease, the applications could be widespread.

Conclusion

Electrical stimulation shows strong potential to boost healing by reprogramming macrophages. These findings highlight new paths for treating injuries and inflammatory disease. More research is needed, but the results point toward powerful future therapies.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pexels.

Autumn brings many things: cooler weather, pumpkin carving, and longer walks outside. Yet the season also carries a downside—rising rates of respiratory illness.

The Nimbus variant of COVID-19 was uncovered in the summer of 2025. Now, as fall begins, another newly identified variant has appeared: Stratus, more formally known as XFG. Stratus is a recombinant virus, formed from two variants, LF.7 and LP.8.1.2. It first emerged in Canada but has since spread worldwide.

What Should You Know About Stratus?

Experts believe Stratus may be a major driver of recent U.S. case surges, though Nimbus still plays a role. CDC wastewater data now mark COVID-19 activity as very high across 19 states.

Stratus, like its sibling variant Nimbus, belongs to the Omicron subtype of COVID-19. More than 1,000 such sublineages already exist, each carrying its own nickname from experts. Regardless of designation, all these variants fall under the same COVID-19 umbrella.

Omicron sub-variants share predictable features: they spread easily, reproduce in the upper respiratory tract, and tend to cause less severe symptoms. However, their mutations allow them to better evade the immune system, keeping their overall public health impact comparable to earlier variants.

What Symptoms Are Linked to Stratus?

Symptoms of Stratus largely mirror those of other Omicron subtypes. Common signs include cough, fatigue, congestion, headache, and sometimes fever. Gastrointestinal issues may also appear.

Like Nimbus, Stratus is marked by throat-related symptoms. While Nimbus became known for “razor throat,” Stratus seems to cause hoarseness, leaving voices scratchy or raspy. Though not yet confirmed through formal studies, medical professionals have observed these patterns anecdotally.

On August 29, the European Centre for Disease Prevention and Control added Stratus to its list of variants under monitoring. Alongside Nimbus and LP.8.1, Stratus remains under close watch for global spread. The next classification levels are “variant of interest” and then “variant of concern” (VOC), though no current strain has yet reached VOC status.

Does the COVID-19 Vaccine Protect against Stratus?

Experts say the current COVID-19 vaccine should still offer protection against Stratus. In addition to vaccination, other precautions remain important: wearing a mask, using air filtration or ventilation, avoiding crowded spaces, and practicing social distancing.

In September, a federal vaccine advisory panel debated changes to vaccine access. One proposal to require a prescription was rejected, but the panel did vote to recommend COVID-19 vaccination primarily for adults 65 and older. For younger groups, the guidance suggests weighing risks and benefits based on complication potential.

The CDC generally follows the panel’s advice, though authorization rests with acting director Jim O’Neill, who replaced Susan Moneriz after her removal earlier this year.

Conclusion

Stratus adds yet another layer to the evolving COVID-19 landscape. Its spread, symptoms, and potential impact highlight the importance of ongoing vigilance. Vaccination and protective measures remain the best tools for reducing risk.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pexels.

For as long as mosquitoes have been biting humans, one question has persisted: what makes certain people so tasty? Is it bananas, garlic, clothing color, or blood type?

Most of these common beliefs have no evidence behind them. But a recent field experiment may finally offer some real clarity. Researchers found that certain hedonistic habits made people more attractive to mosquitoes—specifically beer drinking, sleeping with partners, and skipping sunscreen.

How Did Researchers Test Mosquito Attraction?

In August 2023, researchers from Radboud University Medical Center tested what makes some people more attractive to mosquitoes. They built a lab from connected shipping containers that held about 1,700 Anopheles mosquitoes, a malaria vector responsible for millions of deaths worldwide.

Festival-going volunteers—465 in total—first filled out a short survey, then blew into a clear test cage to release carbon dioxide, a key mosquito signal of nearby humans. Next, they pressed a forearm against a perforated panel that allowed scents to pass through without risk of bites. Over three-minute trials, cameras recorded each attempt as mosquitoes tried to land on the arm site. The study’s results now appear as a preprint in bioRxiv.

What Truly Attracts Mosquitoes?

The results revealed that beer drinkers faced more attempted bites. Those who had consumed alcohol within the last 12 hours experienced about 33% more landings than abstainers, a trend that remained even after cross-analysis with other variables. In contrast, reported substances like cannabis, cocaine, and ecstasy showed no consistent effects on mosquito attraction.

Sleeping habits also mattered. Volunteers who slept in tents or beds with partners attracted more mosquitoes than those who slept alone, with a similar increase to that seen in beer drinkers. Sunscreen had the opposite effect, almost halving landings. Researchers suggested it might mask attractive odors or that active ingredients directly repel mosquitoes.

Blood type, long rumored to be a factor, showed no noticeable impact. Of the more than 400 people tested, only four experienced no attempted bites at all. The team also explored whether skin bacteria played a role, noting some association with Streptococcus on common landing sites, though no strong correlation could be confirmed. As the authors summarized, mosquitoes “simply have a taste for the hedonist among us.”

Applications and Limitations

Sarah Blanken, the study’s lead author at Radboud, cautioned against reading too much into the findings. Rather than giving up summer pleasures, she recommends simple protections like long-sleeved shirts, insect repellent, and sunscreen.

The researchers also noted several limitations. Unlike controlled lab studies, this trial took place in a lively, crowded festival environment. Volunteers may not represent the average population—after all, skipping a Billie Eilish set to test mosquito appetites suggests unusual enthusiasm for science. It’s also possible that some of the most carefree festival-goers opted out, either by oversleeping or staying busy in the crowd.

Still, the experiment offers rare insight into how lifestyle habits shape mosquito attraction. While myths about bananas or blood type don’t hold up, mosquitoes do seem to find pleasure-seekers more attractive.

Conclusion

A recent field experiment tested 465 festival-goers to uncover what attracts mosquitoes. Beer drinking, sleeping with a partner, and skipping sunscreen all increased landings. Researchers recommend simple protections like wearing sunscreen, repellent, and long sleeves.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pexels.

COVID-19 cases are stable or declining across most U.S. states. The CDC reports 36 states show declining or likely declining infections. Only one state shows growth, while 10 states remain unchanged. In some U.S. states and territories, the data is still inconclusive.

Even with cases dropping, new COVID-19 treatments remain essential. Future surges or infectious new variants could still emerge. Researchers are actively seeking therapies to lower risks for patients.

A study from King’s College London tested inhaled heparin. Results showed lower risk of severe complications and reduced need for ventilation. The drug also showed promise for other respiratory infections

How Does Heparin Help Treat COVID-19?

Researchers studied nearly 500 patients hospitalized with COVID-19. Participants represented six countries across multiple hospital settings.

Results showed inhaled heparin cut the risk of ventilation by half. Patients also had a much lower risk of dying compared to traditional care.

Normally, heparin is injected into patients to break down blood clots. In this study, researchers tested an inhaled form of the drug. The aim was to deliver treatment directly to the lungs.

Heparin has anticoagulant, anti-inflammatory, and antiviral properties. Earlier studies confirmed it improved breathing and oxygenation in patients.

Future Testing and Study Limitations

Researchers caution more investigation is needed before general use. They recommend further testing in other serious respiratory infections, such as pneumonia. These illnesses often begin from multiple viruses or bacteria.

The drug may be especially useful for patients with suppressed immunity. This includes cancer patients who develop respiratory infections. Future trials in Europe will test inhaled heparin against flu and RSV. Researchers also aim to create improved inhalation formulations. Better delivery methods may boost effectiveness even further.

The study still had important limitations. Not all research sites used blinded, placebo-controlled conditions. This was only true in the U.S., while other countries did not. Protocols also varied between hospitals, including delivery methods and doses. Heparin itself may have been prepared using different sources. These differences could have affected results, though overall findings were consistent.

Another limitation is that patients already on ventilators were excluded. The drug’s effects in the most severe cases remain unknown. A future meta-trial will explore outcomes in intubated patients. Oxygenation reports were also inconsistent across studies. Still, results point to strong promise for inhaled heparin treatment.

Conclusion

Inhaled heparin shows strong promise as a new COVID-19 therapy. The drug may also help treat pneumonia, flu, and RSV. Continued trials could expand its role in protecting vulnerable patients.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pexels.

When I had Valley Fever, I spent months facing misdiagnoses. At one point, I received intravenous antibiotics at an urgent care clinic. Because Valley Fever is a fungal infection, those antibiotics could not help. Misapplied treatments like this add to a larger crisis: antibiotic resistance.

The Centers for Disease Control and Prevention (CDC) recently issued an alarming report on NDM-producing, carbapenem-resistant Enterobacterioles (NDM-CREs). These are dangerous strains of bacteria that resist nearly all antibiotics. The study, published in Annals of Internal Medicine, shows infections rose more than 460% between 2019 and 2023.

NDM-CRE infections can include pneumonia, bloodstream infections, urinary tract infections, and wound infections. They are extremely hard to treat and can be fatal. Detection is also difficult, since many clinical labs lack the tools to identify them.

What Are NDM-CRE Infections?

New Delhi metallo-β-lactamase (NDM) is the enzyme behind NDM-CRE. This enzyme makes bacteria resistant to nearly all approved antibiotics. As a result, NDM-CRE infections have very limited treatment options.

These strains were once rare in the United States. Because of this, health professionals may not identify them quickly enough. That delay can result in inadequate or misapplied treatments.

NDM-CRE infections carry high rates of fatality and serious complications. The bacteria also spread rapidly, threatening hospitals, clinics, schools, and other vulnerable settings.

Why Are NDM-CRE Infections Spreading?

There are several reasons why NDM-CRE bacteria are spreading so quickly. Poor hand hygiene, insufficient PPE, and inadequate disinfection are major factors. Another is the lack of proper detection tools. Without them, NDM-CRE strains may go unnoticed or be misdiagnosed.

Because of this, the CDC strongly urges health providers to stay alert. Providers should track the spread of NDM-CRE in their local areas. They should also be able to identify the specific carbapenem resistance present in an infection. This knowledge can guide which antibiotics, if any, might still be effective.

Who is Most at Risk from NDM-CRE Infections?

The people at highest risk for NDM-CRE infections are in healthcare settings. Transmission is especially likely in patients with suppressed immune systems. Equipment such as ventilators, urinary catheters, or IV lines can increase the risk of spread. Patients receiving long courses of antibiotics are also more vulnerable.

NDM-CRE spreads through physical contact. This can include unwashed hands, infected wounds, or stool. The CDC advises that people prescribed antibiotics follow their provider’s instructions carefully. Patients should also complete the full course, even if symptoms improve.

Transmission of NDM-CRE from animals is considered unlikely. Still, consulting a veterinarian about a pet’s medical history may be worthwhile.

Conclusion

NDM-CRE infections are rising rapidly and pose serious health threats. Limited treatments and difficult detection make prevention especially important. Strong hygiene, careful antibiotic use, and provider awareness are critical to slowing their spread.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pexels.

In October 2020, then 69-year-old Chicago resident Linda Tomcow tested positive for COVID-19. A chest X-ray later showed pneumonia after several weeks of illness. In May 2021, she began cognitive rehabilitation for ongoing symptoms. Doctors also found mild brain scarring caused by COVID-19.

The scarring was believed to be behind her severe brain fog symptoms. Tomcow sought help from many specialists, including a pulmonologist and neurologist. She also visited a neuropsychologist, psychiatrist, occupational therapist, and physical therapist.

Tomcow represents thousands who live with Long COVID brain fog. This broad term refers to lasting fatigue and cognitive difficulties. In one recent study, researchers used brain imaging to find a biomarker. The biomarker was connected to brain fog in Long COVID patients.

What is the Connection between Brain Fog and Long COVID?

Over 80 percent of people with Long COVID experience brain fog symptoms. This type of cognitive impairment makes work and daily life harder. Hundreds of millions of Long COVID cases continue worldwide. The condition is now considered a major global health burden.

Long COVID is also seen as a threat to economic stability. Its root biological causes remain debated among researchers. Some studies used imaging to show changes in patient brain structure. But these findings could not fully explain molecular causes of impairment.

Molecules that help neurons communicate are very difficult to study. Before this study, no concrete biomarkers confirmed a Long COVID diagnosis. Biomarkers are critical tools for guiding treatment and drug development. They also help researchers design more effective Long COVID medicines.

What Biomarker Did Researchers Link to Brain Fog Symptoms?

New research published in Brain Communications may explain Long COVID brain fog. A team from Yokohama City University’s Graduate School of Medicine led the study. They focused on AMPA receptors, also called AMPARs, which are vital for memory. AMPARs have also been studied in psychiatric and neurological disorders.

Previous research linked AMPARs to depression, bipolar disorder, schizophrenia, and dementia. Researchers developed a new imaging method to directly see AMPAR density. This allowed them to count and measure the receptors in brain tissue.

The study compared 30 Long COVID patients with 80 healthy participants. Patients with Long COVID showed a sharp increase in AMPAR density. This receptor overexpression correlated directly with cognitive impairment symptoms.

Researchers also found multiple inflammatory markers alongside the higher AMPAR levels. This suggests that receptor oversaturation may be triggering brain inflammation. The study proposes this as a cause of Long COVID brain fog.

Conclusion

A recent study links AMPAR brain receptor overexpression to brain fog in Long COVID. Increased receptor density also appeared with inflammatory markers in patients. These findings may explain cognitive symptoms and guide future treatments.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pixabay.

Most people recognize the flu through familiar symptoms like fever and fatigue. Others rely on nasal swab tests to confirm infection with the influenza virus. But a third, unusual way of sensing the flu may soon arrive: tasting it.

Researchers recently developed a molecular sensor that produces a flavor when it detects influenza. The study, published in ACS Central Science, envisions the sensor embedded in gum or lozenges. This would allow people to screen for flu at home with a simple taste.

Such a tool could help reduce flu transmission by alerting people who might not realize they are contagious.

How Would a Gum or Lozenge Sensor Help Reduce Flu?

Sick people staying home is crucial to stopping the flu’s spread. Yet, many become contagious before they feel any symptoms. This makes early detection a major challenge for preventing transmission.

Current flu tests have significant limits. PCR tests using nasal swabs are highly accurate but slow and costly. Lateral flow tests are quicker and more affordable, but often fail to detect infections before symptoms appear.

The study’s authors suggest their new approach could mark a breakthrough. By allowing earlier and easier flu detection, such tools could play a key role in reducing spread.

How Would the Sensor Screen for Flu Virus?

Researchers designed a molecular sensor that releases flavor when it meets influenza virus. The flavor compound, thymol, is easily detectable on the tongue.

The sensor works by mimicking part of the flu virus called neuraminidase. This glycoprotein, which makes up the “N” in strains like H1N1, helps flu viruses break down bonds on host cells. Weakened cells then become more open to infection.

To build the sensor, researchers created a neuraminidase layer and attached thymol molecules to it. When influenza viruses encounter the sensor in gum or lozenges, they detach the thymol. This mimics how the virus breaks down bonds during infection, leaving thymol free to trigger a taste signal.

How Did the Researchers Test the Flu Sensor?

The study confirmed the sensor’s effectiveness through lab tests using human saliva. Samples came from people already infected with influenza. Within 30 minutes of exposure, the sensors released thymol.

Importantly, the sensor showed no side effects on cell function in human or mouse saliva. Human clinical trials are still about two years away. These trials will test whether the sensor can release a detectable flavor both before and after symptoms appear.

If successful, the findings could lead to gum or lozenges containing the sensors. These simple tools would offer fast, accessible flu screening at home. Widespread use could lower infections and reduce flu deaths worldwide.

Conclusion

A new sensor could make flu testing faster and more accessible. Gum or lozenges with the sensor may help people detect infection early. Widespread use could reduce flu cases and save lives.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pexels.

In March 2020, then 14-year-old Kitty McFarland was living an active lifestyle. She spent her time dancing ballet, paddle boarding, running, and playing netball. That spring, Kitty contracted COVID-19. She developed a cough and fever, and at one point her mother recalls finding her frighteningly unresponsive.

Though her symptoms eased at first, Kitty’s health sharply declined a month later. Severe illness left her bedridden for eight months. She missed large portions of school, while doctors struggled to provide answers. Kitty describes living with Long COVID as being “on a roller coaster forever,” with constant, unpredictable ups and downs.

Kitty’s experience is far from unique. Recent research published in Lancet Infectious Diseases shows that children and teens are especially vulnerable. The study found that people under 21 are twice as likely to develop Long COVID after a second infection compared to their first. Many had assumed later infections would be milder, but the findings challenge that belief.

Higher Risk of Long COVID after Reinfection

The study evaluated data from nearly 500,000 people under age 21. It was part of the National Institutes of Health’s RECOVER Initiative, a program designed to study Long COVID. Researchers compiled electronic health records from 40 children’s hospitals across the U.S., analyzing cases from January 1, 2022, to October 13, 2023. Most cases were Omicron infections, though researchers believe the findings apply to newer variants like Nimbus and Stratus.

Over six months, the study found that 1,884 people per million developed Long COVID after two infections. This was twice the rate of those with only one infection, measured at 904 per million. The findings challenge earlier assumptions that later infections are less severe.

Researchers also flagged widespread misdiagnosis. Tens of thousands of children without a COVID-19 diagnosis were treated for symptoms matching Long COVID, such as breathing problems and abdominal discomfort. This suggests the study’s estimates may understate the true impact. Even with conservative data, the CDC reports that about 1.3% of U.S. children under 18—around 1 million young people—have experienced Long COVID symptoms.

Severe Health Risks Linked to Reinfections

The study also measured specific health risks linked to multiple infections. Overall, children and young adults were 3.6 times more likely to develop myocarditis after a second infection compared to those infected only once. Myocarditis, a dangerous heart inflammation, can be fatal and is a known complication of Long COVID and other illnesses.

Participants were also 2.8 times more likely to experience problems with taste and smell. They were 2.3 times more likely to form blood clots. In addition, young people with two infections were nearly twice as likely to develop cardiovascular disease or kidney injury.

The data showed some patterns. Those who developed Long COVID after a second infection were more likely to have pre-existing chronic conditions. Still, researchers noted that many affected youth had no prior health conditions at all.

Vaccination status played a significant role. About three-quarters of the study participants had not received a COVID-19 vaccine. Unvaccinated youth faced higher risks of the most severe symptoms, including myocarditis. While the study was not designed to evaluate vaccine effectiveness, its findings suggest that vaccines reduce the chance of dangerous outcomes.

Despite this evidence, U.S. Health Secretary Robert F. Kennedy has advised against COVID-19 vaccination for healthy children. The study’s authors argue that their data strongly contradicts his position.

Conclusion

Long COVID continues to pose serious risks for children and teens. Reinfections raise the chances of severe health problems, including heart and kidney issues. The latest research shows many young people remain vulnerable, especially those unvaccinated.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.

Image courtesy of Pexels.

Skepticism and misinformation make chronic fatigue syndrome an isolating illness. In a previous study, almost 70% of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) patients reported facing high stigma. A third of ME/CFS patients and half of male patients had suicidal thoughts.

Both medical professionals and community members often fail to recognize the disease. This lack of recognition leads to inadequate support for patients. Many people with ME/CFS are dismissed or misunderstood when describing their severe symptoms.

A recent study in the Journal of Translational Medicine may help reduce stigma. Researchers identified a specific blood signature in patients with severe ME/CFS. They developed a diagnostic test using 200 bloodline markers. The test can identify ME/CFS with 96% accuracy.

These findings offer hope for patients long dismissed or doubted. A reliable diagnostic tool could validate their suffering and improve medical support.

How Did Researchers Create Their New ME-CFS Blood Test?

Researchers built their new ME-CFS test to track epigenetic changes. These changes reflect how gene expression shifts due to environmental or behavioral factors. The test was developed using a pre-existing platform called EpiSwitch®. This system allowed researchers to examine epigenetic regulators in 47 patients with severe ME-CFS symptoms.

The team compared these results with data from 61 healthy participants. They identified 200 epigenetic markers that correctly diagnosed ME-CFS 96% of the time. This strong accuracy rate suggests the test could be a breakthrough for diagnosis.

EpiSwitch® has a proven track record in other medical applications. It helped researchers develop diagnostic tests for prostate cancer. However, ME-CFS is far more complex to diagnose. Its symptoms vary widely from person to person, making consistency difficult.

Experts still don’t know whether all ME-CFS cases share a single cause. It’s possible that multiple factors interact to worsen the disease’s effects. Many ME-CFS symptoms also resemble those of other conditions, complicating diagnosis.

What Concerns and Steps Remain Before This Test Can Be Used?

This discovery offers hope to those who have long suffered with ME-CFS. Many patients have faced years of misunderstanding and misdiagnosis. However, several organizations and medical professionals remain cautious about these findings.

The study found a strong systemic signal in patients with severe ME-CFS. This signal helped distinguish patients from healthy participants. Yet, when compared directly to healthy controls, the signal weakened. Researchers also did not include data from patients with mild or moderate ME-CFS.

The results were not compared to other conditions with similar symptoms. For a diagnostic test to be considered authoritative, both gaps must be addressed. These comparisons are essential to confirm that the test is accurate and specific.

The ME Association UK issued a statement regarding the new blood test. The group emphasized the need for high sensitivity and specificity to ME-CFS alone. Future research should show that the test can distinguish between early and late stages. It should also separate mild, moderate, and severe disease presentations.

The organization concluded that more studies are needed before the test can be used clinically. Until then, ME-CFS patients will need to wait for verified diagnostic tools.

Conclusion

A new ME-CFS blood test could transform diagnosis for many patients. Researchers must still confirm its accuracy across all disease stages and severities. If future studies succeed, this test could offer long-awaited validation and support.

Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.

Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.